Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Enteric Disease Testing Market $6.8 Billion by 2029

The global market for enteric disease testing predicted to reach $6.8 billion by 2029, growing steadily at a CAGR of 5.5% over the forecast period, driven by increasing demand for molecular diagnostic methods of early detection and prognosis of enteric diseases, wider application base in rapid molecular diagnostics, and untapped market in developing countries.

Global Enteric Disease Testing Market

Enteric disease is caused by the presence of foreign antigen such as bacterial, viral and parasites. Enteric pathogens such as Salmonella, Shigella and Yersinia,  Escherichia coli,  Campylobacter,  Clostridium difficile cause symptoms ranging from mild gastroenteritis to life-threatening systemic infections and severe diarrhea.

  • In addition to the acute risks, long-term complications of enteric diseases include malnutrition, malabsorption of vital drugs, and immunological complications.
    • Companies are adopting various strategies for the development of novel testing technologies for enteric diseases.

Every year, millions of cases of food-borne illness and thousands of associated deaths occur in the United States, and the illness burden is even higher in developing countries.

  • Various national Government agencies’ epidemiology and surveillance groups are tracking pathogens and identifying sources for bacterial enteric (intestinal) infections transmitted by food and other routes.

Traditional diagnostic microbiology is increasingly adopting molecular methods as front line tests for a variety of enteric pathogens (EP).

  • Culture-independent diagnostic tests (CIDTs) are increasingly used to identify enteric pathogens. However, foodborne illness surveillance systems have relied upon culture confirmation to estimate disease burden and identify outbreaks through molecular subtyping.
    • The emergence of various advance cost effective technologies such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are expected to boost the growth of this market.
      • Similarly, the nucleic acid amplification tests (NAAT) for viruses are well established as the gold standard, and an increasing number of commercial multi-target assays are now available for bacteria and parasites.
  • Laboratory-based surveillance provides crucial information for assessing food-borne disease trends.
    • However, because only a small proportion of illnesses are diagnosed and reported, periodic assessments of total episodes of illness are also needed.
  • The sensitivity, specificity, and associated positive and negative predictive values of antigen tests for enteric pathogens also differ from those of culture, which makes it difficult to include the results of such tests as part of the definition of reportable diseases.
    • For example, in 2017, Foodborne Diseases Active Surveillance Network (FoodNet) received reports of 24,484 illnesses, 5,677 hospitalizations, and 122 deaths in its surveillance area, which includes 15% of the U.S. population.
      • The incidence of infections with CampylobacterListeria, non-O157 Shiga toxin–producing Escherichia coli (STEC), YersiniaVibrio, and Cyclospora increased.
      • Clinical laboratories are steadily increasing the use of culture-independent diagnostic tests (CIDTs), particularly DNA-based syndrome panels, to diagnose enteric pathogens.
  • Enteric diseases like shigella, one of the leading causes of diarrhea in infants and young children, kills more than 2,000 children under age five die every day.

The global enteric disease testing market report estimates the market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR% 2023 to 2029).

The global market for enteric disease testing segmented by causal organism [bacterial agents (Clostridium difficile, Campylobacteriosis, cholera, E. coli, H. pylori, salmonellosis, shigellosis); viral agents (norovirus, rotavirus); parasitic agents (amebiasis, cryptosporidiosis, giardiasis)], and geography.

  • Based on causal organism categories, the bacterial agents segment accounted for the largest share of the total enteric disease testing market, owing to presence of large number of causal agents, followed by parasitic agents.
  • Among all the causal organisms, the giardiasis parasitic agent segment dominated the global market, whereas the cholera bacterial infection segment anticipated to witness the fastest growth rate throughout the coming years.
    • Giardiasis spreads through contaminated food or water or by person-to-person contact. It’s most common in areas with poor sanitation and unsafe water.
      • According to WHO estimates, globally around 200 million people get infected with giardiasis.
    • Cholera is caused by eating food or drinking water contaminated with a bacterium called Vibrio cholerae.
      • The prevalence is high in low income and developing countries including Africa, Asia and Latin American countries.

The global enteric disease diagnosis market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America and European regions having maintained a high level of hygiene and sanitation infrastructure have observed very low levels of enteric disease epidemics and incidences.
    • In the developed region, multiple public health surveillance systems exist nationally for enteric illnesses to monitor disease burden and trends, investigate individual cases, detect outbreaks, and characterize microorganisms to detect emerging strains.
      • However, significant levels of food and beverage contamination that has led to increased incidence of diseases such as salmonellosis, shigellosis, giardiasis, cholera and campylobacteriosis in these regions.
        • For example, in the United States, 48 million foodborne enteric illnesses occur annually, resulting in 128,000 hospitalizations and 3,000 deaths.
  • On the other hand, the Asia Pacific, Latin America and Rest of the World have been identified as the most attractive regions for the potential to develop into large enteric disease testing market in the near future.
    • The key drivers boosting the market growth in developing regions include high prevalence in developing countries, rising public awareness campaigns by hygiene product manufacturers, and access to technologies such as dipsticks and cassettes for rapid disease testing.
      • In addition, increasingly, hospitals and clinical laboratories in the developing regions are adopting culture-independent diagnostic tests (CIDTs) to identify enteric pathogens to guide clinical decision making due to their increased sensitivity (80%–100%) and specificity (88%–99%), rapid turnaround time, ability to detect multiple pathogens in one test, lower cost, and less technical expertise needed compared to culture methodology.

The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances.

Major competitors operating in the global enteric disease diagnostics market and included in this report are Abbott Laboratories, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad Laboratories, Inc., Coris BioConcept SPRL, Danaher Corporation (Cepheid, Inc.), DiaSorin S.p.A., Meridian Bioscience, Inc., Quest Diagnostics, Inc., and Trinity Biotech plc.

  • Causal Organism
    • Bacterial Agents
      • Clostridium difficile Infection
      • Campylobacteriosis
      • Cholera
      • E. coli Infection
      • H. pylori Infection
      • Salmonellosis
      • Shigellosis
    • Viral Agents
      • Norovirus Infection
      • Rotavirus Infection
    • Parasitic Agents
      • Amebiasis
      • Cryptosporidiosis
      • Giardiasis
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Becton, Dickinson & Company
    • Biomerica, Inc.
    • bioMérieux S.A.
    • Bio-Rad Laboratories, Inc.
    • Coris BioConcept SPRL
    • Danaher Corporation (Cepheid, Inc.)
    • Diasorin S.p.A.
    • Meridian Bioscience, Inc.
    • Quest Diagnostics, Inc.
    • Trinity Biotech plc

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com